Bio-Rad Laboratories (BIO) Gains 5.33% for June 23

Equities Staff  |

Shares of Bio-Rad Laboratories Inc. - Class A (NYSE:BIO) traded 5.33% up on June 23 to close at $505.58.

161,316 exchanged hands. Their current average 30 day volume is 189,863 shares.

Bio-Rad Laboratories has moved 36.47% year-to-date in 2022.

The company is set to release earnings on 2022-07-28.

For technical charts, analysis, and more on Bio-Rad Laboratories visit the company profile.

About Bio-Rad Laboratories Inc. - Class A

Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, its products advance the discovery process and improve healthcare. Bio-Rad's customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020.

To get more information on Bio-Rad Laboratories Inc. - Class A and to follow the company's latest updates, you can visit the company's profile page here: Bio-Rad Laboratories Inc. - Class A's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content